Rocket Lab's Iridium Calculus: When a Falling Share Price Rewrites Its Own Deal Terms

Rocket Lab's stock fell 19.4% in seven sessions despite record Q2 revenue and $2.36B backlog, driven by merger deal mechanics and SpaceX FCC filing.

There is a particular kind of market selloff that confounds the fundamentals-first investor: the stock that slides even as the underlying business posts one record after another. Rocket Lab has spent the past week embodying that paradox, and the mechanics behind the decline say more about modern merger financing than they do about the company's operational health.

The numbers tell a story of a business firing on all cylinders. Second-quarter revenue hit $234.1 million, up 62 percent year over year, while the backlog swelled to $2.36 billion — a 137 percent jump. The company guided third-quarter revenue to between $250 million and $265 million with gross margins of 29 to 31 percent on a US GAAP basis. Yet the stock has fallen for seven consecutive sessions, shedding 19.4 percent and roughly $10 billion in market value, according to media reports, even as the broader market declined only modestly.

Friday's close of €55.60 capped a week that saw the shares lose 11 percent, including a 4.1 percent drop on the final trading day alone. The stock now sits about 18 percent below its 50-day moving average and roughly 58 percent beneath the 52-week high of €133.80 set in May. The RSI reading of 34.8 hints at oversold conditions, though the 73 percent annualized volatility suggests the market is still far from settled on how to price this growth story.

A Regulatory Complaint With a Built-In Amplifier

The trigger for the recent slide was not a profit warning or a missed delivery. It was a filing from SpaceX with the Federal Communications Commission, raising concerns about potential spectrum interference from future Starlink gateways involving Iridium. Crucially, SpaceX is not opposing Rocket Lab's planned $8 billion acquisition of Iridium — it is simply requesting closer scrutiny during the license transfer process.

That distinction mattered little to the market, which knocked 6 percent off the stock on the news. The outsized reaction stems from the deal's structure itself. Each Iridium share is to be exchanged for $27 in cash plus a variable number of Rocket Lab shares, calculated based on the ten-day volume-weighted average price shortly before closing. The arithmetic is unforgiving: when Rocket Lab's stock falls, the exchange ratio shifts automatically, meaning any negative news becomes a self-reinforcing drag on the transaction's terms.

Market observers note that relatively few investors have fully grasped this mechanism, which converts regulatory noise into compounding share-price pressure. The complaint itself was not the problem — the deal architecture that amplified it was.

The timeline for the merger remains intact. Rocket Lab reaffirmed the roadmap on August 10, the US antitrust waiting period expired on August 12, SEC registration documents have been filed, and FCC applications for license transfers have been pending since August 10. Iridium shareholders are scheduled to vote on the combination on September 24. Until then, every piece of market-moving news carries the potential to alter the exchange ratio.

Defense Wins and Operational Momentum

Beneath the share-price turbulence, the operational cadence has rarely looked stronger. The US Space Force awarded Rocket Lab a $981 million contract under the NITE-STAR program, alongside a $397 million order for flat, stackable satellites for threat tracking under the Golden Dome missile-defense initiative and $266 million for missile defense and an Alaska launch site. The company also secured $12 million for a data network consortium and was admitted to the expanded Space Data Network alongside Northrop Grumman, Lockheed Martin and Amazon LEO for Government.

Commercial momentum has followed: Kepler Communications booked the first dedicated Neutron mission, Viasat selected Rocket Lab for a jamming-resistant satellite for security applications, and the 93rd Electron mission launched on August 20. The company has also established Rocket Lab Germany GmbH as a regional hub for constellation manufacturing, with the Neutron rocket still targeted for late 2026.

The Profitability Gap That Won't Close

Yet the operational wins have not translated into the bottom-line improvement investors want to see. The second-quarter loss of $0.08 per share missed expectations by two cents, and free cash flow remained deeply negative at minus $77.4 million. The after-hours reaction to those figures — a 7 percent drop — signaled that the market's patience for growth at any cost is wearing thin.

The defense contracts, for all their strategic significance, are fixed-cost-heavy programs with long lead times. They fill the backlog but do little to explain why operating losses have barely narrowed despite record revenue. The as-yet-undisclosed terms of the Iridium acquisition add another layer of uncertainty around future capital requirements, as does the simultaneous investment across multiple fronts: the Neutron development, German expansion and constellation manufacturing capacity.

Insider activity has done little to soothe nerves. COO Frank Klein sold roughly 35,600 shares for about $2.4 million in late August under a pre-arranged trading plan. Several other executives also sold shares under similar plans, primarily to cover tax obligations from equity compensation — and all retained the majority of their holdings afterward. These sales are routine in form, but in a period of acute share-price sensitivity, they add to the ambient unease.

A Structural Feature of Modern Deal-Making

What makes this episode instructive beyond Rocket Lab itself is the feedback loop now embedded in large-scale acquisitions. When billion-dollar mergers are structured with variable stock components, the acquirer's share price becomes a playing field for competitors and regulators alike. A rival's regulatory filing can, through the indirect route of deal mechanics, influence the price ultimately paid for the target.

That is not a sign of corporate weakness. It is a structural characteristic of contemporary merger financing — one that investors are still learning to price in. For Rocket Lab, the path to renewed market confidence runs through converting backlog growth into actual profitability. Until then, the stock remains a bet on the future rather than a confirmation of the present, caught between record operational performance and the unforgiving mathematics of its own deal structure.